Market Closed -
Nasdaq
04:00:00 2024-04-29 pm EDT
|
5-day change
|
1st Jan Change
|
6.66
USD
|
-1.33%
|
|
+9.36%
|
+72.54%
|
Fiscal Period: December |
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
328.5
|
63.03
|
139.7
|
292.6
|
-
|
-
|
Enterprise Value (EV)
1 |
328.5
|
63.03
|
139.7
|
292.6
|
292.6
|
292.6
|
P/E ratio
|
-1.09
x
|
-1.1
x
|
-3.68
x
|
-5.13
x
|
-5.43
x
|
-5.11
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
-
|
3.84
x
|
7.01
x
|
50.2
x
|
23.6
x
|
23.4
x
|
EV / Revenue
|
-
|
3.84
x
|
7.01
x
|
50.2
x
|
23.6
x
|
23.4
x
|
EV / EBITDA
|
-6.59
x
|
-1.15
x
|
-3.61
x
|
-4.22
x
|
-3.31
x
|
-
|
EV / FCF
|
-7.57
x
|
-1.43
x
|
-4.19
x
|
-5.49
x
|
-6.65
x
|
-5.67
x
|
FCF Yield
|
-13.2%
|
-70.1%
|
-23.9%
|
-18.2%
|
-15%
|
-17.6%
|
Price to Book
|
-
|
-
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
27,579
|
30,745
|
36,192
|
43,347
|
-
|
-
|
Reference price
2 |
11.91
|
2.050
|
3.860
|
6.750
|
6.750
|
6.750
|
Announcement Date
|
3/24/22
|
3/23/23
|
3/7/24
|
-
|
-
|
-
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
-
|
-
|
16.4
|
19.94
|
5.83
|
12.38
|
12.5
|
EBITDA
1 |
-
|
-49.87
|
-54.95
|
-38.74
|
-69.32
|
-88.3
|
-
|
EBIT
1 |
-22.4
|
-50.09
|
-56.06
|
-40.5
|
-61.98
|
-67.96
|
-78.51
|
Operating Margin
|
-
|
-
|
-341.78%
|
-203.09%
|
-1,063.16%
|
-549.02%
|
-628.05%
|
Earnings before Tax (EBT)
1 |
-
|
-49.98
|
-53.81
|
-37.37
|
-56.58
|
-59.02
|
-77.94
|
Net income
1 |
-
|
-201.9
|
-53.81
|
-37.37
|
-59.16
|
-62.76
|
-77.94
|
Net margin
|
-
|
-
|
-328.09%
|
-187.37%
|
-1,014.78%
|
-506.98%
|
-623.56%
|
EPS
2 |
-3.240
|
-10.94
|
-1.860
|
-1.050
|
-1.316
|
-1.244
|
-1.320
|
Free Cash Flow
1 |
-
|
-43.37
|
-44.21
|
-33.38
|
-53.28
|
-43.97
|
-51.58
|
FCF margin
|
-
|
-
|
-269.54%
|
-167.38%
|
-914.01%
|
-355.21%
|
-412.64%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
2/26/21
|
3/24/22
|
3/23/23
|
3/7/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q3
|
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
---|
Net sales
1 |
-
|
-
|
-
|
4.148
|
4.97
|
7.283
|
4.464
|
8.081
|
5.897
|
1.501
|
1.457
|
1.457
|
1.457
|
1.457
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-3.703
|
-6.709
|
-12.5
|
-
|
-
|
-
|
-
|
EBIT
1 |
-13.8
|
-17.88
|
-15.37
|
-14.97
|
-12.54
|
-13.18
|
-12.22
|
-6.067
|
-9.251
|
-12.96
|
-14.19
|
-14.88
|
-12.23
|
-17.31
|
Operating Margin
|
-
|
-
|
-
|
-360.95%
|
-252.29%
|
-180.96%
|
-273.81%
|
-75.08%
|
-156.88%
|
-863.56%
|
-973.64%
|
-1,021.29%
|
-839.47%
|
-1,187.71%
|
Earnings before Tax (EBT)
1 |
-13.76
|
-17.87
|
-15.34
|
-14.59
|
-11.94
|
-11.93
|
-11.98
|
-5.098
|
-8.285
|
-12
|
-13.18
|
-13.79
|
-9.792
|
-15.62
|
Net income
1 |
-13.76
|
-17.87
|
-15.34
|
-14.59
|
-11.94
|
-11.93
|
-11.98
|
-5.098
|
-8.285
|
-12
|
-13.61
|
-14.35
|
-11.36
|
-16.48
|
Net margin
|
-
|
-
|
-
|
-351.83%
|
-240.3%
|
-163.81%
|
-268.41%
|
-63.09%
|
-140.5%
|
-799.67%
|
-933.91%
|
-984.32%
|
-779.71%
|
-1,130.62%
|
EPS
2 |
-0.5100
|
-0.6600
|
-0.5600
|
-0.5300
|
-0.4000
|
-0.3900
|
-0.3400
|
-0.1400
|
-0.2300
|
-0.3300
|
-0.3500
|
-0.3240
|
-0.2280
|
-0.3420
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
11/10/21
|
3/24/22
|
5/10/22
|
8/11/22
|
11/10/22
|
3/23/23
|
5/11/23
|
8/10/23
|
11/14/23
|
3/7/24
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
|
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-43.4
|
-44.2
|
-33.4
|
-53.3
|
-44
|
-51.6
|
ROE (net income / shareholders' equity)
|
-400%
|
-39.1%
|
-32%
|
-65.6%
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
Cash Flow per Share
2 |
-2.320
|
-1.410
|
-0.9100
|
-2.220
|
-1.710
|
-
|
Capex
1 |
-
|
3.61
|
0.77
|
7.64
|
9.14
|
11.8
|
Capex / Sales
|
-
|
22.02%
|
3.86%
|
131.05%
|
73.84%
|
94.24%
|
Announcement Date
|
3/24/22
|
3/23/23
|
3/7/24
|
-
|
-
|
-
|
Last Close Price
6.75
USD Average target price
12.5
USD Spread / Average Target +85.19% Consensus |
1st Jan change
|
Capi.
|
---|
| +72.54% | 293M | | +1.77% | 42.75B | | +47.70% | 41.61B | | +12.24% | 41.34B | | -8.83% | 26.59B | | +7.44% | 25.49B | | -23.01% | 18.12B | | +30.56% | 12.24B | | -1.82% | 11.76B | | +8.35% | 11B |
Other Biotechnology & Medical Research
|